uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec in Huntington's Disease Showing Continued Slowing of Disease Progression 29 September
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec in Huntington's Disease 02 September
